OLOPATADINE HYDROCHLORIDE
RxNorm 1111339· OPHTHALMIC
Alembic Pharmaceuticals Inc.
Indications and usage
INDICATIONS AND USAGE Olopatadine hydrochloride ophthalmic solution USP, 0.1% is indicated for the treatment of the signs and symptoms of allergic conjunctivitis.
Dosage and administration
DOSAGE AND ADMINISTRATION The recommended dose is one drop in each affected eye two times per day at an interval of 6 to 8 hours.
Warnings
WARNINGS Olopatadine hydrochloride ophthalmic solution USP, 0.1% is for topical use only and not for injection or oral use.
Contraindications
CONTRAINDICATIONS Olopatadine hydrochloride ophthalmic solution USP, 0.1% is contraindicated in persons with a known hypersensitivity to olopatadine hydrochloride, USP or any components of olopatadine hydrochloride ophthalmic solution USP, 0.1%.
Pregnancy
PREGNANCY Pregnancy Category C. Olopatadine was found not to be teratogenic in rats and rabbits. However, rats treated at 600 mg/kg/day, or 93,750 times the MROHD and rabbits treated at 400 mg/kg/day, or 62,500 times the MROHD, during organogenesis showed a decrease in live fetuses. There are, however, no adequate and well controlled studies in pregnant women. Because animal studies are not always predictive of human responses, this drug should be used in pregnant women only if the potential benefit to the mother justifies the potential risk to the embryo or fetus.
Nursing mothers
NURSING MOTHERS Olopatadine has been identified in the milk of nursing rats following oral administration. It is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities in the human breast milk. Nevertheless, caution should be exercised when Olopatadine hydrochloride ophthalmic solution USP, 0.1% is administered to a nursing mother.
Adverse events
Most frequently reported events (FDA FAERS). Report frequency does not imply causation.
- treatment failure1,943
- drug ineffective731
- device delivery system issue701
- product use in unapproved indication650
- drug dose omission by device518
- product use issue463
- eye irritation296
- vision blurred236
- headache218
- condition aggravated178
- eye discharge177
- eye pain177
- nausea176
- device issue164
- fatigue160
- eye pruritus153
Adverse reactions (label)
ADVERSE REACTIONS Headaches have been reported at an incidence of 7%. The following adverse experiences have been reported in less than 5% of patients: Asthenia, blurred vision, burning or stinging, cold syndrome, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, nausea, pharyngitis, pruritis, rhinitis, sinusitis, and taste perversion. Some of these events were similar to the underlying disease being studied.
View more: Full FDA label on DailyMed →Label effective 20190221